Blue Owl Capital Holdings LP Buys New Stake in Immuneering Corporation $IMRX

Blue Owl Capital Holdings LP bought a new stake in shares of Immuneering Corporation (NASDAQ:IMRX) during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 550,000 shares of the company’s stock, valued at approximately $3,850,000. Immuneering comprises about 1.2% of Blue Owl Capital Holdings LP’s holdings, making the stock its 25th biggest position. Blue Owl Capital Holdings LP owned about 1.32% of Immuneering at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in IMRX. Dimensional Fund Advisors LP lifted its position in shares of Immuneering by 46.4% in the third quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock valued at $137,000 after acquiring an additional 6,196 shares in the last quarter. Kingsview Wealth Management LLC boosted its stake in shares of Immuneering by 542.9% during the third quarter. Kingsview Wealth Management LLC now owns 90,000 shares of the company’s stock valued at $630,000 after acquiring an additional 76,000 shares during the last quarter. Monashee Investment Management LLC purchased a new stake in Immuneering during the 3rd quarter worth about $2,100,000. TD Asset Management Inc purchased a new stake in Immuneering during the 3rd quarter worth about $1,016,000. Finally, Palumbo Wealth Management LLC acquired a new position in Immuneering in the 3rd quarter valued at about $343,000. 67.65% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on IMRX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a report on Monday, December 29th. Wall Street Zen raised shares of Immuneering from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Chardan Capital reissued a “buy” rating and set a $20.00 price objective on shares of Immuneering in a research note on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Insider Transactions at Immuneering

In related news, Director Thomas J. Schall acquired 21,645 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were acquired at an average cost of $4.67 per share, for a total transaction of $101,082.15. Following the acquisition, the director directly owned 74,530 shares in the company, valued at approximately $348,055.10. The trade was a 40.93% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Peter Feinberg bought 20,000 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was bought at an average cost of $4.35 per share, for a total transaction of $87,000.00. Following the completion of the transaction, the director directly owned 135,441 shares of the company’s stock, valued at approximately $589,168.35. The trade was a 17.32% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have bought 51,819 shares of company stock valued at $234,472. Corporate insiders own 22.90% of the company’s stock.

Immuneering Stock Up 7.0%

Shares of NASDAQ:IMRX opened at $5.33 on Friday. The company has a market cap of $344.16 million, a P/E ratio of -2.99 and a beta of 0.46. The business has a fifty day simple moving average of $5.22 and a 200-day simple moving average of $6.08. Immuneering Corporation has a 52 week low of $1.10 and a 52 week high of $10.08.

Immuneering (NASDAQ:IMRX) last released its earnings results on Friday, March 6th. The company reported ($0.18) earnings per share for the quarter. Sell-side analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.

Immuneering Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.